Hepatocellular carcinoma - Molecular pathogenesis and novel targets for therapy;Hepatozelluläres Karzinom - molekulare Grundlagen und Zielmoleküle für die Therapie

Deutsche Medizinische Wochenschrift

Volumn 137, Issue 16, 2012, Pages 855-860

  Marquardt, J U ^a   Galle, P R ^a   Teufel, A ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

gene expression profile; hepatocellular carcinoma; liver cancer; molecular pathogenesis; targeted therapy

Indexed keywords

LIVER CELL CARCINOMA; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; REVIEW;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84859534576     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0032-1304843     Document Type: Review

References (20)

1. Andersen JB, Factor VM, Marquardt JU et al. An integrated genomic and epigenomic approach predicts therapeutic response to zebularine in human liver cancer. Sci Transl Med: 2010; 2 54ra77
2. Calvisi DF, Ladu S, Gorden A et al. Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest: 2007; 117 2713 2722 (Pubitemid 47494371)
3. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer: 2006; 6 674 687 (Pubitemid 44286000)
4. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer: 2004; 4 143 153 (Pubitemid 38198742)
5. Hoshida Y, Villanueva A, Kobayashi M et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med: 2008; 359 1995 2004
6. Krawczyk M, Mullenbach R, Weber SN et al. Genome-wide association studies and genetic risk assessment of liver diseases. Nat Rev Gastroenterol Hepatol: 2010; 7 669 681
7. Lee JS, Thorgeirsson SS. Genetic profiling of human hepatocellular carcinoma. Sem in Liver Dis: 2005; 25 125 132 (Pubitemid 40781065)
8. Marquardt JU, Galle PR, Teufel A. Molecular diagnosis and therapy of hepatocellular carcinoma (HCC); An emerging field for advanced technologies. J Hepatol: 2012; 56 267-277
9. McDermott U, Downing JR, Stratton MR. Genomics and the continuum of cancer care. N Engl J Med: 2010; 364 340 350
10. Meyerson M, Gabriel S, Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet: 2011; 11 685 696
11. Mott JL. MicroRNAs involved in tumor suppressor and oncogene pathways: implications for hepatobiliary neoplasia. Hepatology: 2009; 50 630 637
12. Paradis V, Zalinski S, Chelbi E et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology: 2009; 49 851 859
13. Sherman M. Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. Semin Liver Dis: 2010; 30 3 16
14. Thorgeirsson SS. Genomic decoding of hepatocellular carcinoma. Gastroenterology: 2006; 131 1344 1346 (Pubitemid 44498720)
15. Um TH, Kim H, Oh BK et al. Aberrant CpG island hypermethylation in dysplastic nodules and early HCC of hepatitis B virus-related human multistep hepatocarcinogenesis. J Hepatol: 2011; 54 939 947
16. Villanueva A, Hoshida Y, Battiston C et al. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology: 2011; 140 1501 1512.e2
17. Villanueva A, Newell P, Chiang DY et al. Genomics and signaling pathways in hepatocellular carcinoma. Sem in Liver Dis: 2007; 27 55 76
18. Woo HG, Park ES, Lee JS et al. Identification of potential driver genes in human liver carcinoma by genomewide screening. Cancer Res: 2009; 69 4059 4066
19. Worns MA, Galle PR. Novel inhibitors in development for hepatocellular carcinoma. Expert Opin Investig Drugs: 2010; 19 615 629
20. Zender L, Villanueva A, Tovar V et al. Cancer gene discovery in hepatocellular carcinoma. J Hepatol: 2010; 52 921 929